Floatz logo

Inomax

Schizophrenia

Beth Israel Deaconess Medical CenterPhase 2Active
CCC
55/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
49/ 100
Competitive Position
65/ 100

Competitive context

135 Active assets in the Schizophrenia cohort.

Asset / SponsorPhaseRating
Xanomeline
European Group for Research In Schizophrenia
Phase 4BBB
TROSPIUM
European Group for Research In Schizophrenia
Phase 4BBB
Lurasidone
Aziende Chimiche Riunite Angelini Francesco S.p.A
Phase 4BBB
PALIPERIDONE PALMITATE , (R)-
Jiangsu Province Nanjing Brain Hospital
Phase 4BBB
Asenapine
Noven Pharmaceuticals, Inc.
Phase 4BBB

View all 50 →

Same molecule, other indications

Inomax is also rated in:

Acute Chest SyndromeDormant
BB
Indicative ·
64 / 100
View asset →
Hemorrhagic StrokeDormant
B
Indicative ·
62 / 100
View asset →
Pulmonary HypertensionDormant
B
Indicative ·
61 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →